The Oncology Institute logo

Latest News

Abstracts Authored by TOI Physicians Accepted to ASCO


Earlier this month, three abstracts co-authored by TOI physicians were accepted to ASCO. TOI Physicians are committed to advancing cancer research and contributing to the development of cutting-edge cancer treatments. Both clinical trials included in these abstracts have the potential to positively impact patient lives.

Dr. Michael Chung contributed to a Phase 3 clinical trial treating diffuse large B-cell lymphoma. This drug is a possible treatment for patients who have exhausted many other treatment options and are ineligible for an autologous stem cell transplant.

Dr. Merrill Shum participated in a trial for a drug that targets a new mutation in Non-Small Cell Lung Cancer patients. The trial is expanding to 200+ patient participants in 20 counties, and TOI will serve as one of the host sites.

Dr. Omkar Marathe served as a PI for a trial of a topical ointment treatment for Hand-Foot Skin Reaction (HFSR). Currently, there is no FDA approved treatment for HFSR, which leads to decrease in quality of life for patients and interruptions in dosing.

With more than 130 clinical trials offered at TOI, we bring leading-edge therapies to our patients while contributing to the advancement of cancer treatment for patients around the word. Congratulations to Drs. Chung and Shum on this accomplishment!

You can read more about Dr. Chung’s abstract and Dr. Shum’s abstract and Dr. Marathe’s abstract on the ASCO website.

Skip to content